書籍詳細

2 呼吸器系ウイルス

P.18 掲載の参考文献

• 1) Sugaya N, Mitamura K, Yamazaki M, Tamura D. Ichikawa M, Kimura K et al.: Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44(2):197-202, 2007.
  pubmed

• 2) Sugaya N, Takeuchi Y: Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin Infect Dis 41(7):939-947, 2005.
  pubmed

• 3) Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436):759-765, 2004.
  pubmed

• 4) Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K et al.: Emergence of infiuenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297(13) :1435-1442, 2007.
  pubmed

• 5) 菅谷憲夫:10代のインフルエンザ患者の治療はどうすべきかoseltamivirと異常行動. 転落事故. 日本医事新報 4360:64-68, 2007.

• 6) Fuke C, Ihama Y, Miyazaki T: Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu((R)). Leg Med(Tokyo), 2007.

• 7) Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M:Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 272(14):1122-1126, 1994.
  pubmed

• 8) Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA:Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165(3):265-272, 2005.
  pubmed

• 9) Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V: Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366(9492):1165-1174, 2005.
  pubmed

• 10) Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH:Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic:aquantitative analysis. Lancet 368(9554):2211-2218, 2006.

3 中枢神経系ウイルス

P.41 掲載の参考文献

• 1) 高山直秀著:「ヒトの狂犬病-忘れられた死の病」. 時空出版, 2000. Jackson AC, Wunner WH(eds): Rabies. Academic Press出版, 2002.

• 2) 狂犬病ウイルスを神経系のネットワークを探るプローブとした研究の総説: Kelly RM, Strick PL:Rabies as a transneuronal tracer of circuits in the central nervous system. J Neurosci Methods 103(1):63-71, 2000.

• 3) cDNA発現系における機能的な狂犬病ウイルス糖蛋白質合成条件の研究: Sakai M, Kankanamge PJ, Shoji J, Kawata S, Tochikura T, Kawai A: Studies on the conditions required for structural and functional maturation of rabies virus glycoprotein (G) in G-cDNA-transfected cells. Microbiol Immunol 48(11): 853-864, 2004.

• 4) 個別に精製した材料から組み立てた遺伝子導入用人工ウイルス粒子の報告:Shoji J, Tanihara Y, Uchiyama T, Kawai A:Preparation of virosomes coated with vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells. Microbiol Immunol 48(3):163-174, 2004.

5 皮膚ウイルス感染症(発疹性ウイルス感染症)

P.60 掲載の参考文献

• 1) Oldstone MBA:Measles virus. In Viruses, Plaques, & History. Oxford, 1998, p73-89.

• 2) http://www. who. int/mediacentre/factsheets/fs286/en/

• 3) 多屋馨子:感染症の話:麻疹. 国立感染症研究所感染症情報センター. http://idsc. nih. gojp/idwr/kansen/k03/k03_03/k03_03. html

P.67 掲載の参考文献

• 1) Nahmias AJ, Dowdle WR:Antigenicand biologic differences in herpesvirus hominis. Prog Med Virol 10:110-159, 1968.
  pubmed

• 2) Rawls WE, Tompkins WA, Melnick JL: The association of herpesvirus type 2 and carcinoma of the uterine cervix. Am J Epidemiol 89:547-554, 1969.
  pubmed

• 3) 川名尚, 坂元正一, 吉野亀三郎: 外陰ヘルペス症からのHSV-I, IIの分離成功例について. 日本産婦人科学会誌 24:873-874, 1972.

• 4) Kawana T, Kawaguchi T, Sakamoto S: Clinical and virological studies on genital herpes, Lancet 30:2(7992):964, 1976.

• 5) 西澤美香, 川名尚, 村田照夫, 西井 修:女性性器ヘルペス初感染例における型特異的血清診断に関する研究. 日本性感染症学会誌 16: 97-103, 2005.

• 6) 川名尚, 橋戸円:微量中和法による型別抗単純ヘルペスウイルス抗体測定の評価. 臨床とウイルス 19: 347-351, 1991.

• 7) Nahmias AJ, Dowdle WR, Wickliffe Get al.: Clinical Aspects of Infection with Herpes Simplex Viruses 1 and 2. The Human Herpes Viruses. (eds. Nahmias AJ, Dowdle WR, Schinazi R), Elsevier, 1981, p3-9.

• 8) Lafferty WE, Coombs RW, Benedetti Jet al.: Recurrences after oral and genital herpes simplex virus infection. Infuence of site of infection and viral type. N Engl J Med 316:1444-1449, 1987.

• 9) Yoshikawa T, Hill JM, Stanberry LR et al.: The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region. J Exp Med 184:659-664, 1996.
  pubmed

• 10) 野原道子, 薮田光紀, 川名尚:急性性器ヘルペスに排尿障害を伴うElsberg症候群の1例. 日産婦東京地方部会誌 37:383-386, 1988.

• 11) Aurelius E, Forsgren M, Gille E et al.: Neurologic morbidity after herpes simplex virus type 2 meningitis: are trospective study of 40 patients. Scand J Infect Dis 34:278-283, 2002.

• 12) Hashido M, Lee FK, Nahmias AJ et al.: An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays. Epidemiol Infect 120:179-186, 1998.
  pubmed

• 13) Fleming DT, McQuillan GM, Johnson RE et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 337:1105-1111, 1997.
  pubmed

• 14) Patel R, Tyring S, Strand A et al.: Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 75:398-402, 1999.
  pubmed

• 15) Corey L, Wald A, Patel R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350:11-20, 2004.
  pubmed

• 16) Obara Y, Furuta Y, Takasu T et al.: Distribution of herpes simplex virus types 1 and 2 genomes in human spinal ganglia studied by PCR and in situ hybridization. J Med Virol 52:136-142, 1997.
  pubmed

• 17) Itoh N, Matsumura N, Ogi A et al.: High prevalence of herpes simplex virus type 2 in acute retinal necrosis syndrome associated with herpes simplex virus in Japan. Am J Ophthalmol 129:404-405, 2000.
  pubmed

• 18) Landry ML, Mullangi P, Nee P et al.: Herpes simplex virus type 2 acute retinal necrosis 9 years after neonatal herpes. J Pediatr 146:836-838, 2005.
  pubmed

• 19) Wald A, Ericsson M, Krantz E et al.: Oral shedding of herpes simplex virus type 2. Sex Transm Infect 80:272-276, 2004.
  pubmed

6 遺伝子治療とウイルスベクター

P.72 掲載の参考文献

• 1) Kuroya M et al.: Tohoku J Exp Med 58:62, 1953.
  pubmed

• 2) DeMeio JL et al.: Proc Soc Exp Biol and Med 98:453-458, 1958.
  pubmed

• 3) Slobod KS et al.: Vaccine 22:3182-3186, 2004.
  pubmed

• 4) Okada Y et al.: Med J Osaka Univ 7:709-717, 1957.

• 5) Furusawa M et al.: Nature 248:449-450, 1974.

• 6) Uchida Y et al.: J Cell Biol 80:10-20, 1979.

• 7) Nakanishi M et al.:Exp Cell Res 159:399-409, 1985.
  pubmed

• 8) Kato A et al.:Genes to Cells 1:569-579, 1996.

• 9) Nishimura K et al.: J Biol Chem 282:27383-27391, 2007.

• 10) Goto T et al.: Pharm Res 23:384-391, 2006.
  pubmed

9 悪性腫瘍とウイルス

P.89 掲載の参考文献

• 1) Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994.

• 2) Moore PS, Chang Y: Fields Virology. Forth Edition. Philadelphia, Lippincott Williams&Wilkins, 2001, p2803-2833.

• 3) Aoki Y, Tosato G: HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus(KSHV)infectivity. Blood 104:810-814, 2004.
  pubmed

• 4) Coscoy L: Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7:391-401, 2007.
  pubmed

P.91 掲載の参考文献

• 1) 高田賢蔵・監修, 柳井秀雄・清水則夫・編: EBウイルス. 診断と治療社, 2003.

• 2) Kelly G, Bell A, Rickinson A: Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8:1098-1104, 2002.
  pubmed

• 3) Kanda T, Yajima M, Ahsan N et al.: Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J Virol 78:7004-7015, 2004.
  pubmed

P.93 掲載の参考文献

• 1) Katase K, Teshima H, Hirai Y, Hasumi K:Natural history of cervical human papillomavirus lesions. Intervirology 38(3-4):192-194, 1995.
  pubmed